Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 291,500 shares, an increase of 97.0% from the February 28th total of 148,000 shares. Based on an average daily trading volume, of 566,700 shares, the short-interest ratio is currently 0.5 days. Currently, 10.6% of the company’s stock are short sold.

Institutional Trading of Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. Cetera Investment Advisers acquired a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 70,006 shares of the company’s stock, valued at approximately $116,000. Cetera Investment Advisers owned about 2.53% of Palisade Bio at the end of the most recent reporting period. 11.79% of the stock is owned by institutional investors and hedge funds.

Palisade Bio Stock Up 1.5 %

NASDAQ:PALI traded up $0.01 during mid-day trading on Friday, reaching $0.70. The company’s stock had a trading volume of 25,056 shares, compared to its average volume of 761,427. Palisade Bio has a 1 year low of $0.65 and a 1 year high of $9.65. The stock has a fifty day moving average of $1.04 and a 200-day moving average of $2.11. The firm has a market capitalization of $1.94 million, a PE ratio of -0.05 and a beta of 1.49.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($2.39) by $1.70. On average, analysts expect that Palisade Bio will post -12.43 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.